XJPX
2927
Market cap78mUSD
Oct 09, Last price
848.00JPY
1D
0.24%
1Q
-1.51%
Jan 2017
3.79%
IPO
-39.43%
Name
AFC-HD AMS Life Science Co Ltd
Chart & performance
P/E
8.52
P/S
0.38
EPS
99.49
Div yield, %
4.02%
Shrs. gr., 5y
0.01%
Rev. gr., 5y
15.60%
Revenues
32.66b
+8.18%
Net income
1.45b
+15.69%
CFO
1.79b
+16.02%
Dividend
Aug 28, 202622 JPY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
AFC-HD AMS Life Science Co., Ltd. operates as an original equipment manufacturer of health foods and cosmetics. The company operates through five segments: Healthcare, Pharmaceutical, Department Store, Food and Beverage, and Other Business. The Healthcare segment manufactures, sells, and supplies OEM health foods, such as tablets, capsules, granules, soft drinks, and jelly; and cosmetics, including skin care and hair care products. This segment also operates as an advertising agency focused on planning and producing health information programs, and publishing health information magazines. The Pharmaceutical segment manufactures and sells Chinese herbal medicine, over-the-counter medicines, and generic medicines. The Department Store segment engages in the wholesale of watches, jewelry, and precious metal products. The Food and Beverage segment operates restaurants. The Other Business segment engages in the real estate buying, selling, management, rental, and intermediary business; construction industry; tourism, travel and hotel industry; and school lunch business. AFC-HD AMS Life Science Co., Ltd. was founded in 1969 and is headquartered in Shizuoka, Japan.
Key people
Shunji Sasahara
President of Subsidiaries, Director · since 2021
Shigeki Tamura
Executive Director · since 2005
Enoyuki Maekawa
Director of General Affairs, Director · since 2022
Chairman of the Board, Representative Director · since 2021
Shigenori Fukuchi
Senior Managing Director · since 2017
Nobue Hamabe
Director of Accounting , Director · since 2022
Yasuhiro Matsunaga
President, Representative Director · since 2021
Shigeho Minamikata
Manager of Chairman's Office, President of Subsidiary, Director · since 2021
Kazunori Takada
Chief Director of Administration, Director · since 2021
Naoya Unno
Chief Director of Technology Development, Director · since 2003
Yosuke Aikawa
Independent Director · since 2021
Masaki Takahashi
Independent Director · since 2020
Hiroshi Umino
Independent Director · since 2020
Valuation
Title JPY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑08 | 2024‑08 | 2023‑08 | 2022‑08 | 2021‑08 | 2020‑08 | 2019‑08 | 2018‑08 | 2017‑08 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||